Seminars in Hematology
Volume 46, Supplement 2 , Page S1, January 2009

The Changing Landscape of Secondary ITP: Introduction

Platelet Disorders Center, Division of Pediatric Hematology-Oncology, Weill Cornell Medical College of Cornell University, New York, NY

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 STATEMENT OF CONFLICT OF INTEREST: James B. Bussel, MD, discloses the following: Consultant/Advisory Board: Amgen, GSK, Ligand, Baxter; Speaker Programs: Baxter; Investigator: Amgen, GSK, Ligand, BiogenIdec, Cangene, Genentech, Genzyme, Immunomedics, MGI Pharma, Sysmex; Stockholder (Spouse): Amgen, GSK.

PII: S0037-1963(08)00201-1

doi:10.1053/j.seminhematol.2008.12.002

Seminars in Hematology
Volume 46, Supplement 2 , Page S1, January 2009

Article Tools